# NCT03055013 (NCT03055013)

> Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03055013
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma
- Interventions: Nephrectomy; Nivolumab; Patient Observation; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 819
- Primary outcome: Recurrence-free Survival (RFS) Rate at 5 Years

## Commentary we found

- YouTube: 4
- Podcasts: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03055013